List of Excipients in Branded Drug ZEVTERA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
La Jolla Pharmaceutical Company	ZEVTERA	ceftobiprole medocaril sodium	68547-578	CITRIC ACID MONOHYDRATE	2034-04-03
La Jolla Pharmaceutical Company	ZEVTERA	ceftobiprole medocaril sodium	68547-578	SODIUM HYDROXIDE	2034-04-03
Basilea Pharmaceutica International AG Allschwil	ZEVTERA	ceftobiprole medocaril sodium	84312-001	CITRIC ACID MONOHYDRATE	2034-04-03
Basilea Pharmaceutica International AG Allschwil	ZEVTERA	ceftobiprole medocaril sodium	84312-001	SODIUM	2034-04-03

Last updated: September 24, 2026

ZEVTERA (ceftobiprole medocaril sodium) has a commercially relevant excipient profile because its current product is a lyophilized intravenous powder requiring reconstitution and dilution. The main opportunity is not to alter the active antibiotic, but to improve hospital handling through ready-to-use presentations, higher stability, lower preparation time, and compatibility with existing infusion systems. The reference product contains sodium carbonate and is supplied in single-dose vials. Any new presentation would require a regulatory strategy based on pharmaceutical equivalence, bioequivalence, or a 505(b)(2) pathway, depending on the product design.

ZEVTERA Excipient Strategy, Formulation Patents, and Commercial Opportunities

What is ZEVTERA and how is it formulated?

ZEVTERA is an injectable formulation of ceftobiprole medocaril sodium, a prodrug converted in vivo to the active cephalosporin ceftobiprole. The U.S. Food and Drug Administration approved ZEVTERA on March 14, 2024, for adults with Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis, acute bacterial skin and skin-structure infections, and bacterial community-acquired pneumonia [1].

The approved dosage form is a sterile, preservative-free lyophilized powder for intravenous infusion.

Product attribute	ZEVTERA profile
Active ingredient	Ceftobiprole medocaril sodium
Active cephalosporin	Ceftobiprole
Dosage form	Lyophilized powder for injection
Strength	667 mg ceftobiprole medocaril sodium, equivalent to 500 mg ceftobiprole
Primary excipient identified in U.S. labeling	Sodium carbonate
Reconstitution	Sterile water for injection
Further dilution	Compatible intravenous infusion solutions identified in the prescribing information
Administration	Intravenous infusion over approximately two hours
U.S. applicant	Basilea Pharmaceutica International Ltd.
U.S. approval date	March 14, 2024
Regulatory exclusivity	Five-year new chemical entity exclusivity, subject to statutory exceptions

The product’s excipient system is intentionally limited. That supports a lower excipient-related immunogenicity and tolerability profile but leaves room for commercial improvement in container closure, reconstitution, dilution, and in-use stability.

What excipients does ZEVTERA contain?

The U.S. prescribing information identifies sodium carbonate as the principal inactive ingredient in the vial. The formulation does not rely on a complex surfactant, lipid, polymer, or preservative system [2].

Sodium carbonate has several functional roles:

1. It helps control the pH of the lyophilized formulation.
2. It supports chemical stability during manufacture and storage.
3. It assists reconstitution of the ceftobiprole medocaril sodium cake.
4. It contributes to the final sodium load administered to the patient.

The excipient strategy is therefore conventional for a sensitive beta-lactam injectable: minimize formulation complexity, use a buffering or alkalizing agent, and protect the active substance through lyophilization.

The commercial limitation is operational rather than pharmacological. Hospital staff must reconstitute the vial, transfer the solution into an infusion container, and administer the dose over a relatively long infusion period. Each step creates opportunities for preparation error, contamination, waste, and delayed antibiotic delivery.

What formulation improvements could create commercial value?

The most attractive opportunities are hospital-use improvements that preserve the approved active ingredient and exposure profile.

Ready-to-use infusion bags

A premixed infusion bag could eliminate vial reconstitution and reduce pharmacy labor. The product could be supplied in a single-dose flexible bag containing the labeled dose in an approved infusion solution.

Commercial benefits include:

• Lower preparation time in hospital pharmacies.
• Fewer transfer steps.
• Lower risk of reconstitution errors.
• Reduced use of sterile water and ancillary supplies.
• Easier deployment in emergency departments and smaller hospitals.
• Potentially lower product waste.

The principal technical issue is stability. Ceftobiprole medocaril must remain chemically stable in the selected solution across refrigerated and room-temperature conditions. The sponsor would need to characterize degradation products, pH drift, potency, particulate formation, container interaction, and extractables and leachables.

Dual-chamber or reconstitution-on-demand systems

A dual-chamber vial or bag could separate the lyophilized drug from the diluent until administration. This design would retain a dry product’s storage advantages while reducing manual preparation.

Potential systems include:

• Dual-chamber bags.
• Vial-adapter systems.
• Closed-system transfer devices.
• Pharmacy-ready reconstitution kits.
• Prefilled diluent-plus-vial assemblies.

These presentations may offer stronger intellectual-property positions than a simple change in excipient concentration because the claims can cover the container, compartment geometry, reconstitution mechanism, and use method.

Improved in-use stability

The reference labeling provides specified handling and infusion conditions. A competing or lifecycle product could seek longer stability after reconstitution or dilution.

An improved stability profile could support:

• Batch preparation for scheduled dosing.
• Central pharmacy compounding.
• Overnight preparation.
• Reduced discarded doses.
• Use in outpatient infusion centers.
• Greater compatibility with automated compounding systems.

Stability claims must be supported by validated analytical methods and real-time or accelerated data. The commercial value increases if the formulation remains stable in commonly used solutions such as 0.9% sodium chloride or 5% dextrose and across the temperature range encountered in hospital distribution.

Lower-sodium or alternative-buffer formulations

Sodium carbonate is functional but may create a formulation opportunity for a lower-sodium product or an alternative buffering system. The clinical value would likely be limited because the administered sodium amount is not the principal differentiator for most patients. The commercial value could still arise if an alternative buffer improves:

• Reconstitution speed.
• Solution clarity.
• Compatibility with infusion materials.
• Stability in premixed bags.
• Manufacturing yield.
• Lyophilized cake appearance and robustness.

A buffer substitution would require careful comparison of degradation pathways. Beta-lactam antibiotics can be sensitive to pH, moisture, temperature, and trace-metal exposure. A new buffer would need to improve the total product profile rather than merely reduce one excipient.

What patent opportunities exist for ZEVTERA formulations?

The strongest formulation patent strategy would focus on technically specific improvements rather than broad claims to ceftobiprole medocaril alone.

Potential claim categories include:

Patent area	Commercial purpose
Stabilized aqueous solution	Longer post-reconstitution or post-dilution shelf life
Premixed infusion bag	Eliminates vial preparation
Dual-chamber container	Separates drug and diluent during storage
Specific buffer system	Improves pH control or chemical stability
Excipient concentration range	Protects a defined stability window
Container closure system	Limits moisture ingress and adsorption
Lyophilization cycle	Improves cake structure and reconstitution
Low-particulate formulation	Supports hospital and regulatory quality requirements
Administration method	Covers infusion timing or preparation workflow
Combination presentation	Protects a kit containing drug, diluent, and transfer device

A formulation patent could have commercial value even if the core composition-of-matter rights are approaching expiration. It could delay direct substitution for a hospital-friendly presentation, particularly if the product is listed in the FDA Orange Book and successfully asserted against an abbreviated new drug application.

The practical strength of such patents depends on whether the improved formulation produces an unexpected stability or handling benefit, whether the claims are narrow enough to survive validity challenges, and whether a generic can design around the protected excipient range.

When does ZEVTERA lose exclusivity?

ZEVTERA received five-year new chemical entity exclusivity from its March 14, 2024 approval date. Under the standard statutory framework, that exclusivity generally prevents submission of an ANDA or 505(b)(2) application referencing the active ingredient until March 14, 2029, subject to the statutory patent-certification exception [3].

NCE exclusivity is not the same as patent protection. A patent may expire earlier or later. A generic or 505(b)(2) applicant may also challenge listed patents through a Paragraph IV certification once the relevant application can be submitted.

Milestone	Date or status
FDA approval	March 14, 2024
Five-year NCE exclusivity	Generally through March 14, 2029
Earliest ordinary ANDA filing window	Generally after March 14, 2029, unless a statutory exception applies
Earliest generic launch	Dependent on patents, exclusivity, litigation, and approval timing
Patent expiration	Must be confirmed against the current FDA Orange Book and relevant patent records
Pediatric exclusivity	No confirmed six-month pediatric extension should be assumed without an FDA grant

The commercial planning implication is clear: an improved excipient presentation can be developed during the NCE period, but its regulatory filing and approval timing must account for the prohibition on certain applications before the exclusivity date.

What is the Orange Book and Paragraph IV status of ZEVTERA?

The Orange Book status determines whether listed patents can delay approval of an ANDA. The reference product’s FDA approval establishes the regulatory basis for a future generic, but the ability to list and enforce formulation or method patents depends on the patents meeting FDA listing requirements.

Relevant patent categories may include:

• Drug substance patents.
• Drug product patents.
• Formulation patents.
• Method-of-use patents.

Method-of-use patents may have limited commercial effect if the approved indications are not fully covered by the claims or if a generic uses a section viii statement to omit patented indications. Formulation patents have greater relevance for a ready-to-use product if the generic seeks to copy the same dosage form.

A Paragraph IV challenge could create litigation before generic approval. The patent holder would generally have 45 days after receiving notice to file an infringement action, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework [4].

No generic-entry date should be treated as fixed solely from the FDA approval date. The controlling variables are the current Orange Book listings, patent expiration dates, certifications, litigation, and any settlement agreement.

Which companies are positioned to challenge ZEVTERA?

The most likely challengers are established injectable generic manufacturers with sterile manufacturing capacity, including companies active in hospital anti-infective products. Potential participants in the competitive field include large generic manufacturers, specialty injectable companies, and contract development and manufacturing organizations that license a finished formulation.

A simple vial powder is easier to reproduce than a stable premixed bag. A generic applicant seeking an equivalent lyophilized vial may face fewer technical barriers than a company attempting to commercialize a ready-to-use solution. This creates two competitive tracks:

1. A low-cost vial-based generic after regulatory and patent barriers clear.
2. A differentiated hospital product based on premixing, stability, or preparation efficiency.

The second track could command a price premium if hospitals quantify pharmacy labor, preparation delays, discarded doses, and medication-error risk.

How strong is the excipient and manufacturing barrier?

The manufacturing barrier is moderate for the reference lyophilized vial and higher for a stable premixed product.

Lyophilized vial

Manufacturing requirements include:

• Sterile drug-substance handling.
• Aseptic filling.
• Controlled lyophilization.
• Moisture protection.
• Reconstitution performance testing.
• Container closure integrity.
• Sterility and particulate controls.

These capabilities are available to many injectable generic manufacturers.

Premixed solution

A premixed product requires greater control over:

• Long-term solution stability.
• Drug concentration.
• Bag material compatibility.
• pH and osmolality.
• Particulate burden.
• Terminal sterilization feasibility.
• Leachables and extractables.
• Shipping and temperature excursions.

A premixed product therefore may have a stronger manufacturing and regulatory barrier, even if its active ingredient is no longer protected by strong composition patents.

How does ZEVTERA compare with competing hospital antibiotics?

ZEVTERA competes with other intravenous agents used for serious bacterial infections, including ceftaroline, vancomycin, daptomycin, linezolid, and selected carbapenems. Its commercial positioning is tied to coverage against difficult Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus, combined with activity against selected Gram-negative organisms.

From an excipient and delivery perspective, ZEVTERA’s main differentiation opportunity is operational:

Product strategy	Hospital value
Current vial powder	Familiar sterile injectable format
Premixed bag	Fewer preparation steps
Dual-chamber system	Simplified point-of-care activation
Extended stability	More flexible pharmacy batching
Lower-volume presentation	Potentially easier administration
Closed transfer system	Reduced contamination and handling risk

The formulation opportunity is strongest in hospitals where pharmacy labor and infusion workflow affect antibiotic availability.

What licensing and commercial deals could support ZEVTERA growth?

Basilea can create value through licensing or co-development arrangements covering:

• U.S. commercial rights.
• Regional distribution.
• Premixed infusion technology.
• Dual-chamber container systems.
• Contract sterile manufacturing.
• Hospital supply and group-purchasing access.
• Lifecycle formulations for outpatient infusion.

A technology license could be structured around milestone payments, regional royalties, or supply-based economics. The most defensible deal asset would be a formulation with validated stability and a protected delivery system, rather than a conventional buffer substitution.

What generic launch scenarios are most plausible?

Three launch scenarios are commercially relevant.

Scenario 1: Vial-based generic entry

A generic manufacturer reproduces the lyophilized vial after regulatory exclusivity and patent barriers expire. This would place the greatest pressure on price and hospital contracting.

Scenario 2: Paragraph IV-led entry

A challenger contests listed patents and seeks approval before the expected patent expiration date. Litigation or settlement could establish an earlier launch date.

Scenario 3: Differentiated 505(b)(2) product

A company launches a premixed bag, dual-chamber system, or extended-stability formulation. This product could enter under a separate regulatory strategy and compete on workflow rather than price alone.

Key Takeaways

• ZEVTERA is a lyophilized intravenous ceftobiprole medocaril sodium product containing sodium carbonate as the identified principal excipient.
• The strongest commercial opportunity is a ready-to-use or reconstitution-on-demand presentation.
• Extended post-reconstitution stability could reduce hospital waste and pharmacy workload.
• Alternative buffers may support a lifecycle product, but only if they improve stability, handling, or compatibility.
• Formulation patents should target defined excipient systems, container technologies, lyophilization processes, and stability outcomes.
• ZEVTERA received five-year NCE exclusivity from March 14, 2024, generally extending through March 14, 2029.
• Generic entry will depend on current Orange Book listings, patent certifications, litigation, settlements, and FDA approval timing.
• A premixed product is likely to present a higher technical and regulatory barrier than a conventional vial-based generic.
• Licensing opportunities are strongest in sterile delivery technology, commercial distribution, and hospital workflow optimization.

FAQs

Can ZEVTERA be supplied as a prefilled infusion bag?

Yes, a prefilled bag is technically plausible, but the formulation would require new stability, container-compatibility, sterility, and regulatory data. It would not automatically be substitutable for the approved vial product.

Is sodium carbonate essential to the ZEVTERA formulation?

Sodium carbonate is the identified inactive ingredient in the U.S. vial formulation. A different buffer may be possible, but the replacement would need to maintain chemical stability, reconstitution performance, and product quality.

Would a ready-to-use ZEVTERA formulation qualify as a generic?

Not necessarily. A formulation with a materially different dosage form, excipient system, container, or administration profile may require a 505(b)(2) application rather than a conventional ANDA.

Can a competitor patent a ZEVTERA excipient formulation?

Yes. Patent protection may be available for a novel and non-obvious composition, concentration range, container system, lyophilization process, or stability improvement. The claims must be sufficiently differentiated from known ceftobiprole formulations.

What is the most valuable lifecycle strategy for ZEVTERA?

A stable premixed infusion bag or dual-chamber presentation is likely to have greater commercial value than a simple excipient substitution because it can reduce hospital preparation steps and support differentiated pricing.

References

1. U.S. Food and Drug Administration. (2024, March 14). FDA approves new antibiotic for serious bacterial infections. https://www.fda.gov

2. U.S. Food and Drug Administration. (2024). ZEVTERA (ceftobiprole medocaril sodium) for injection: Prescribing information. Basilea Pharmaceutica International Ltd.

3. U.S. Food and Drug Administration. (2024). New chemical entity exclusivity and FDA regulatory exclusivity provisions. https://www.fda.gov

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. https://www.fda.gov

5. U.S. Congress. (1984). Drug Price Competition and Patent Term Restoration Act of 1984, Pub. L. No. 98-417, 98 Stat. 1585.